Titelia

Holdings of B Group, Inc.

19 declared positions · as of Mar 31, 2026

Original filing · Ten largest lines: 84.1 % of the equity sleeve

Sector breakdown

  • Unattributed 100.0 %

Titelia classification, company by company. The unattributed share stays visible.

Currency breakdown

  • USD 100.0 %

The quoted currency of each line, as declared.

Country breakdown

  • US 85.5 %
  • FR 8.0 %
  • KY 6.5 %

Shares computed on the equity sleeve.

RankCountryLinesValueShare
1US17111.1M $85.47 %
2FR110.4M $8.00 %
3KY18.5M $6.52 %

Positions

RankCompanySharesValueWeight
1ADMA Biologics Inc 3,207,54228.9M $
2Palisade Bio Inc 11,414,28520M $
3Praxis Precision Medicines Inc 33,23710.7M $
4Cellectis SA 3,281,50110.4M $
5ZAI LAB LTD 450,6468.5M $
6Taysha Gene Therapies Inc 1,800,5568M $
7NRX Therapeutics Inc 3,000,0006.4M $
8Structure Therapeutics Inc 127,5006.1M $
9Iovance Biotherapeutics Inc 1,500,0005.3M $
10Spyre Therapeutics Inc 100,0005M $
11Assembly Biosciences Inc 175,7064.9M $
12Aura Biosciences Inc 597,5764M $
13Oruka Therapeutics Inc 75,0003.7M $
14Sight Sciences Inc 970,0003.7M $
15Ultragenyx Pharmaceutical Inc 135,0002.8M $
16Apogee Therapeutics Inc 7,500631.3K $
17Foghorn Therapeutics Inc 102,000487.6K $
18Soleno Therapeutics Inc 7,500251.1K $
19Replimune Group Inc 26,000198.9K $